Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project

Shimoyama, Rai; Imamura, Yoshinori; Uryu, Kiyoaki; Mase, Takahiro; Fujimura, Yoshiaki; Hayashi, Maki; Ohtaki, Megu; Ohtani, Keiko; Shinozaki, Nobuaki; Minami, Hironobu

doi:10.3892/mco.2023.2694

Cited by 3 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…our real-world study, encompassing 846 cases of metastatic pancreatic cancer initially treated between 2010 and 2020, revealed a median OS of just 6.8 months (8).…”

Section: Definitionmentioning

confidence: 83%

“…FOLFIRINOX (including fluorouracil, folinic acid, oxaliplatin, and irinotecan) ( 4 – 6 ) and gemcitabine plus nab-paclitaxel ( 7 ) have been reported as the standard first-line therapies for advanced/recurrent pancreatic cancer, but the prognosis remains poor with median overall survival (OS) of 9–12 months in clinical trials ( 4 , 7 ). Conversely, our real-world study, encompassing 846 cases of metastatic pancreatic cancer initially treated between 2010 and 2020, revealed a median OS of just 6.8 months ( 8 ).…”

Section: Introductionmentioning

confidence: 82%

“…Patients. We identified 846 patients with pathologically or radiologically confirmed primary metastatic pancreatic cancer who underwent first-line chemotherapy at Tokushukai Medical Group hospitals between April 1, 2010, and March 31, 2020 (8). Briefly, the patients were treated with gemcitabine, S-1, gemcitabine plus S-1, gemcitabine plus nab-paclitaxel, or FOLFIRINOX as their first-line treatment.…”

Section: Methodsmentioning

confidence: 99%

“…The objective of this study is to conduct a direct comparison of the various inflammation-based prognostic markers reported to date, utilizing the aforementioned dataset ( 8 ), in order to identify the most accurate markers for assessing prognosis in metastatic pancreatic cancer.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Inflammation‑based prognostic markers of metastatic pancreatic cancer using real‑world data in Japan: The Tokushukai REAl‑world Data (TREAD) project

Shimoyama,

Imamura,

Uryu

et al. 2024

Oncol Lett

Self Cite

View full text Add to dashboard Cite

Inflammation-based prognostic markers based on a combination of blood-based parameters, including the modified Glasgow prognostic score (mGPS), have been associated with clinical outcomes in patients with various types of cancer. The present study aimed to evaluate and compare the accuracy of these previously reported markers in patients with metastatic pancreatic cancer receiving first-line chemotherapy. A total of 846 patients were identified between April 2010 and March 2020 as part of a nationwide real-world study from 46 Tokushukai medical group hospitals in Japan. Blood laboratory data collected within 14 days of starting first-line chemotherapy assessed 17 inflammation-based prognostic markers. Information from patients with no missing data was used to compare the accuracy and performance of the inflammation-based prognostic markers. A total of 487 patients were eligible for this supplemental analysis. The 17 inflammation-based markers demonstrated significant prognostic value. Among them, the concordance rate with overall survival (OS) was highest for mGPS. The median OS time of patients with mGPS 0, 1 and 2 was 8.2, 6.0 and 2.9 months, respectively. Compared with mGPS 0, mGPS 1 and 2 showed hazard ratios of 1.39 (95% confidence interval, 1.07–1.81) and 2.63 (2.00–3.45), respectively. The present real-world data analysis showed that various previously reported inflammation-based markers had significant prognostic value in patients with metastatic pancreatic cancer. Among these markers, the mGPS demonstrated the highest level of accuracy. This trial has been registered in the University Hospital Medical Information Network Clinical Trials Registry as UMIN000050590 on April 1, 2023.

show abstract

“…our real-world study, encompassing 846 cases of metastatic pancreatic cancer initially treated between 2010 and 2020, revealed a median OS of just 6.8 months (8).…”

Section: Definitionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 82%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Inflammation‑based prognostic markers of metastatic pancreatic cancer using real‑world data in Japan: The Tokushukai REAl‑world Data (TREAD) project

Shimoyama,

Imamura,

Uryu

et al. 2024

Oncol Lett

Self Cite

View full text Add to dashboard Cite

show abstract

Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer

Tang,

Yang,

et al. 2024

Pancreatology

View full text Add to dashboard Cite

Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study

Aseafan,

Alfakeeh,

Tashkandi

et al. 2025

BMC Cancer

View full text Add to dashboard Cite

Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited treatment options yielding poor outcomes. This study aimed to evaluate the real-world clinical characteristics, treatment patterns, and outcomes of patients with locally advanced unresectable and de-novo metastatic PDAC in Saudi Arabia, providing regional data to compare with international benchmarks. Methods This is a retrospective, multicentre study involving 350 patients diagnosed with unresectable locally advanced or de-novo metastatic PDAC between January 2015 and November 2023. Data were collected from 10 oncology centers across Saudi Arabia. Results The median age at diagnosis was 60 years, with 63% of patients presenting with multiple metastatic sites, primarily in the liver (66.3%). FOLFIRINOX was the most common first-line treatment (55.1%), followed by gemcitabine plus nab-paclitaxel (15.1%). The median PFS for first-line treatment was 5.3 months, with FOLFIRINOX achieving the longest PFS (6.5 months). The median OS was 10.34 months for the entire cohort, with better survival outcomes observed in patients receiving FOLFIRINOX (12.3 months). Independent prognostic factors for PFS and OS included performance status, first-line regimen, and neutrophil-lymphocyte ratio (NLR). Among patients tested, 7.1% had deficient mismatch repair (d-MMR), and 5.8% harbored BRCA mutations. Conclusions This real-world study confirms that clinical outcomes for locally advanced unresectable and metastatic PDAC in Saudi Arabia are consistent with international data, with FOLFIRINOX showing superior outcomes over gemcitabine-based regimens. However, both treatments reflect the persistent poor prognosis of PDAC, underscoring the need for novel therapeutic strategies. Further research is warranted to optimize treatment selection and improve survival outcomes in this population.

show abstract

Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project

Cited by 3 publications

References 36 publications

Inflammation‑based prognostic markers of metastatic pancreatic cancer using real‑world data in Japan: The Tokushukai REAl‑world Data (TREAD) project

Inflammation‑based prognostic markers of metastatic pancreatic cancer using real‑world data in Japan: The Tokushukai REAl‑world Data (TREAD) project

Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer

Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study

Contact Info

Product

Resources

About